Abbott’s Xience V Drives Fourth-Quarter Vascular Sales Up 60%
This article was originally published in The Gray Sheet
Executive Summary
Abbott's vascular device revenue soared almost 60% in the fourth quarter to $663 million on the strength of the Xience V everolimus-eluting stent, the firm reported Jan. 21